Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDG-PET for predicting the prognosis of malignant lymphoma.

Literature DB >> 7811561

FDG-PET for predicting the prognosis of malignant lymphoma.

J Okada¹, H Oonishi, K Yoshikawa, J Itami, K Uno, K Imaseki, N Arimizu.

Abstract

To evaluate the usefulness of FDG-PET as a predictor of prognosis, 34 patients with untreated malignant lymphoma in the head and neck region were studied. After FDG-PET and treatment, they were observed from 15 to 50 months. Tumors which were aggressive and resistant to treatment tended to show high uptake of FDG. The survival rate of patients with high uptake of FDG, DAR > or = 8, was lower than the rate of the other patients. It is considered to be useful to add FDG uptake of the tumor to other prognostic factors for predicting the prognosis.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 7811561 DOI： 10.1007/bf03164996

Source DB: PubMed Journal: Ann Nucl Med ISSN： 0914-7187 Impact factor: 2.668

15 in total

1. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.

Authors: L K Griffeth; F Dehdashti; A H McGuire; D J McGuire; D J Perry; S M Moerlein; B A Siegel
Journal: Radiology Date: 1992-01 Impact factor: 11.105

2. FDG-PET in oncology: there's more to it than looking at pictures.

Authors: A J Fischman; N M Alpert
Journal: J Nucl Med Date: 1993-01 Impact factor: 10.057

3. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors: C S Patlak; R G Blasberg; J D Fenstermacher
Journal: J Cereb Blood Flow Metab Date: 1983-03 Impact factor: 6.200

4. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.

Authors: L S Gritters; I R Francis; K R Zasadny; R L Wahl
Journal: J Nucl Med Date: 1993-09 Impact factor: 10.057

5. Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant.

Authors: A Gjedde; K Wienhard; W D Heiss; G Kloster; N H Diemer; K Herholz; G Pawlik
Journal: J Cereb Blood Flow Metab Date: 1985-06 Impact factor: 6.200

6. Metabolic imaging of human extremity musculoskeletal tumors by PET.

Authors: K A Kern; A Brunetti; J A Norton; A E Chang; M Malawer; E Lack; R D Finn; S A Rosenberg; S M Larson
Journal: J Nucl Med Date: 1988-02 Impact factor: 10.057

7. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

Authors: S Okazumi; K Isono; K Enomoto; T Kikuchi; M Ozaki; H Yamamoto; H Hayashi; T Asano; M Ryu
Journal: J Nucl Med Date: 1992-03 Impact factor: 10.057

8. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.

Authors: J Okada; K Yoshikawa; M Itami; K Imaseki; K Uno; J Itami; J Kuyama; A Mikata; N Arimizu
Journal: J Nucl Med Date: 1992-03 Impact factor: 10.057

9. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

Authors:
Journal: Cancer Date: 1982-05-15 Impact factor: 6.860

10. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma.

Authors: S Schrape; D B Jones; D H Wright
Journal: Br J Cancer Date: 1987-03 Impact factor: 7.640

16 in total

Review 1. PET in lymphoma.

Authors: Conor D Collins
Journal: Cancer Imaging Date: 2006-10-31 Impact factor: 3.909

FDG-PET for predicting the prognosis of malignant lymphoma.

1. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.

2. FDG-PET in oncology: there's more to it than looking at pictures.

3. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

4. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.

5. Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant.

6. Metabolic imaging of human extremity musculoskeletal tumors by PET.

7. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

8. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.

9. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

10. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma.

Review 1. PET in lymphoma.

Review 2. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Review 3. Where are we with nuclear medicine in pediatrics?

Review 4. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

5. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis.

Review 6. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.

7. PET in T-Cell Lymphoma.

Review 8. FDG-PET imaging in hematological malignancies.

9. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.

Review 10. PET/CT in oncology: for which tumours is it the reference standard?